Sirenas

Sirenas is a San Diego-based, private drug discovery company pioneering the use of computational metabolomics to mine marine and microbiome-derived natural products for novel therapeutics. The company's proprietary ATLANTIS platform analyzes complex metabolomic datasets to rapidly identify bioactive small molecules with potential against high-value targets in areas like oncology, inflammation, and infectious diseases. Founded in 2013 by a team including CEO Eduardo Esquenazi, Sirenas has built a large, sustainably sourced marine sample library and has attracted non-dilutive funding, such as a grant from the Bill & Melinda Gates Foundation. It operates as a preclinical platform company, generating therapeutic leads for potential partnership or internal development.

ATLANTIS: A proprietary computational metabolomics platform that uses advanced algorithms and machine learning to analyze large-scale metabolomic and bioassay datasets from marine and plant extracts. It rapidly identifies novel bioactive small molecule scaffolds and connects them to biological activity for therapeutic lead discovery.

Sirenas competes with other natural product discovery companies (e.g., Lodo Therapeutics, Hexagon Bio) and broader drug discovery platforms using AI/ML. Its differentiation lies in its exclusive focus on marine/metabolomic data, its unique physical sample library, and its highly credentialed scientific team. Competition for partnerships with large pharma is intense.